Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 203
1977 239
1978 231
1979 370
1980 280
1981 287
1982 237
1983 229
1984 297
1985 305
1986 299
1987 285
1988 322
1989 331
1990 279
1991 278
1992 369
1993 283
1994 294
1995 378
1996 295
1997 322
1998 314
1999 393
2000 299
2001 395
2002 398
2003 445
2004 496
2005 555
2006 463
2007 486
2008 501
2009 462
2010 448
2011 635
2012 563
2013 568
2014 614
2015 514
2016 437
2017 380
2018 399
2019 377
2020 370
2021 371
2022 337
2023 256
2024 119

Text availability

Article attribute

Article type

Publication date

Search Results

15,527 results

Results by year

Filters applied: . Clear all
Page 1
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC, Ferreira FR, Silva-Amaral D, Lima DA, Hallak JEC, Zuardi AW, Del-Bel EA, Guimarães FS, Costa KCM, Campos AC, Crippa ACS, Crippa JAS. Pedrazzi JFC, et al. Psychopharmacology (Berl). 2022 Sep;239(9):2713-2734. doi: 10.1007/s00213-022-06196-4. Epub 2022 Jul 29. Psychopharmacology (Berl). 2022. PMID: 35904579 Review.
Editorial.
D'Souza DC, Curran HV. D'Souza DC, et al. Psychopharmacology (Berl). 2022 May;239(5):1143-1145. doi: 10.1007/s00213-022-06110-y. Psychopharmacology (Berl). 2022. PMID: 35316359 No abstract available.
Antipsychotics and risk of QT prolongation: a pharmacovigilance study.
Bordet C, Garcia P, Salvo F, Touafchia A, Galinier M, Sommet A, Montastruc F. Bordet C, et al. Psychopharmacology (Berl). 2023 Jan;240(1):199-202. doi: 10.1007/s00213-022-06293-4. Epub 2022 Dec 14. Psychopharmacology (Berl). 2023. PMID: 36515735
Phosphodiesterase inhibitors in psychiatric disorders.
Sadeghi MA, Nassireslami E, Yousefi Zoshk M, Hosseini Y, Abbasian K, Chamanara M. Sadeghi MA, et al. Psychopharmacology (Berl). 2023 Jun;240(6):1201-1219. doi: 10.1007/s00213-023-06361-3. Epub 2023 Apr 15. Psychopharmacology (Berl). 2023. PMID: 37060470 Review.
The computational psychopathology of emotion.
Erdman A, Eldar E. Erdman A, et al. Psychopharmacology (Berl). 2023 Nov;240(11):2231-2238. doi: 10.1007/s00213-023-06335-5. Epub 2023 Feb 22. Psychopharmacology (Berl). 2023. PMID: 36811651 Review.
Innovating translational models of affective disorders.
Robinson E, Bangasser DA. Robinson E, et al. Psychopharmacology (Berl). 2023 Nov;240(11):2217-2220. doi: 10.1007/s00213-023-06472-x. Psychopharmacology (Berl). 2023. PMID: 37843593 No abstract available.
Xylazine effects on opioid-induced brain hypoxia.
Choi S, Irwin MR, Kiyatkin EA. Choi S, et al. Psychopharmacology (Berl). 2023 Jul;240(7):1561-1571. doi: 10.1007/s00213-023-06390-y. Epub 2023 Jun 21. Psychopharmacology (Berl). 2023. PMID: 37340247 Free PMC article.
The effect of SSRIs on fear learning: a systematic review and meta-analysis.
Heesbeen EJ, Bijlsma EY, Verdouw PM, van Lissa C, Hooijmans C, Groenink L. Heesbeen EJ, et al. Psychopharmacology (Berl). 2023 Nov;240(11):2335-2359. doi: 10.1007/s00213-023-06333-7. Epub 2023 Feb 27. Psychopharmacology (Berl). 2023. PMID: 36847831 Free PMC article. Review.
15,527 results
You have reached the last available page of results. Please see the User Guide for more information.